OTC Markets Group Welcomes Immunovaccine to OTCQX

NEW YORK, April 27, 2015 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine development company, has qualified to trade on the OTCQX® Best Marketplace.

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO

Immunovaccine begins trading today on OTCQX under the symbol "IMMVF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We are pleased to welcome Immunovaccine to the family of investor-friendly U.S. and international companies on OTCQX," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "Trading on OTCQX will provide Immunovaccine's U.S. shareholders transparent trading and convenient access to the company's news and financial disclosure so they can more easily analyze, value and trade its securities. We look forward to supporting Immunovaccine in its continued growth and success in the public markets." 

"The OTCQX offers U.S. investors easier access to Immunovaccine as we expand our presence in the rapidly evolving field of cancer immunotherapy," said Marc Mansour, CEO of Immunovaccine. "Trading on the OTCQX enables us to introduce the company to a broader range of investors and retail brokers in the U.S., at a time when our sector has emerged as one of the most promising in cancer therapy."

Dorsey & Whitney LLP serves as Immunovaccine's Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the company's DepoVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). The company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.

About OTC Markets Group Inc. 
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to inform investors of opportunities and risks: the OTCQX® Best Marketplace; the OTCQB® Venture Marketplace; and the OTC Pink® Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., [phone], [e-mail]

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-immunovaccine-to-otcqx-300072084.html

SOURCE OTC Markets Group Inc.

Copyright 2015 PR Newswire